Mode
Text Size
Log in / Sign up
N/A N=60

Predicting Placental Pathologies by Ultrasound Imaging

Intrauterine Growth Restriction · Villitis · IUGR

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcome: Primary: Number of Participants With Uterine Artery Indices Completed — 13; 3 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Comprehensive Doppler Ultrasound of the Placenta (Diagnostic_test); Verasonics Ultrasound scanner (ultra-sensitive Doppler imaging) (Other)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Mayo Clinic
Primary completion
Jul 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Uterine Artery Indices Completed
13; 3
PRIMARY
Number of Patients With Umbilical Artery Indices Completed
29; 8
PRIMARY
Systolic(S)/Diastolic(D) Ratio
2.8; 2.3
PRIMARY
Resistance Index (RI)
0.6; 0.6
PRIMARY
Pulsatility Index (PI)
1.0; 0.7
PRIMARY
Number of Participants With Placental Pathology Indicating Chronic Villitis
8; 7
SECONDARY
Gestational Age at Birth
39.2; 38.1
SECONDARY
Preterm Labor
2; 0
SECONDARY
Birth Weight of Infant
2598; 3348.5

Summary

Intrauterine growth restriction (IUGR) is caused when the placenta cannot provide enough nutrients to allow normal growth of the fetus during pregnancy. It is unclear why IUGR happens, but an increase in inflammatory T cells in the placenta known as villitis of unknown etiology (VUE) is observed in many IUGR infants. The investigators aim to develop ultrasound methods for diagnosing VUE to understand it's role in IUGR.

Eligibility Criteria

Inclusion Criteria for IUGR study cohort:

  • Pregnancy > 28 weeks gestation
  • Diagnosis of Intrauterine Growth Restriction (IUGR) before admission for labor and delivery
  • Weight > 110 lbs (50 kg)
  • Ability to understand and provide written informed consent

Inclusion Criteria for control cohort:

  • Pregnancy > 28 weeks gestation
  • No known pregnancy complications at prenatal obstetrical visit (+/- 1 week gestational age of matched subject in IUGR cohort)
  • Weight > 110 lbs (50 kg)
  • Ability to understand and provide written informed consent

Exclusion Criteria

  • Known immunodeficiency or pregnancy complication (i.e. preeclampsia or gestational diabetes)
  • Known autoimmune disease (e.g., rheumatoid arthritis or systemic lupus erythematosus) or chronic hypertension
  • Chronic, active viral infections, including HIV-1/2, HTLV-1/2, Hepatitis B or C
  • Solid organ or transplant recipient
  • Current smokers (tobacco exposure within 30 days of registration)
  • Conceptions from assisted reproductive technology (prior Clomid use is allowed)
  • Multiple gestation
  • Ruptured membranes
  • Pregnancy <28 weeks gestation
  • Not planning on delivering at Mayo Clinic
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04506970). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search